Bridgebio Pharma

BBIO53

$22.54arrow_drop_up1.07%$0.23

BBIO53

$22.54

arrow_drop_up1.07%$0.23

Performance History

Key Stats
Open	$22.26
Prev. Close	$22.35
EPS	-2.42
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	21.75	22.99
52 Week Range	21.62	44.32

Ratios







EPS	-2.42

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Bridgebio Pharma (BBIO)

BridgeBio Pharma Inc. (BBIO) is a leading biotechnology company focused on discovering, developing, and delivering innovative medicines to patients with genetic diseases. With a mission to bridge the gap between academic research and the commercialization of life-changing treatments, BridgeBio is dedicated to transforming the lives of patients who have limited or no treatment options. As of the latest market close, BBIO's stock price was $86.25, with a market capitalization of $9.34 billion.

BridgeBio's commitment to genetic diseases is exemplified by its extensive portfolio of programs targeting a range of rare and debilitating conditions. The company's pipeline includes multiple potential therapies in various stages of development, addressing genetic diseases such as oncology, cardiology, dermatology, neurology, and more. These programs are backed by rigorous scientific research and supported by a team of world-class researchers, clinicians, and industry experts.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Neil Kumar Ph.D.
Headquarters: Palo Alto
Employees: 392
Exchange: NASDAQ

Keep an eye on Bridgebio Pharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Bridgebio Pharma 's (BBIO) price per share?

The current price per share for Bridgebio Pharma (BBIO) is $22.54. The stock has seen a price change of $0.24 recently, indicating a 1.07% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Bridgebio Pharma (BBIO)?

For Bridgebio Pharma (BBIO), the 52-week high is $44.32, which is 96.63% from the current price. The 52-week low is $21.62, the current price is 4.26% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Bridgebio Pharma (BBIO) a growth stock?

Bridgebio Pharma (BBIO) has shown an average price growth of -6.8% over the past three years. It has received a score of 84 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Bridgebio Pharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Bridgebio Pharma (BBIO) stock price performance year to date (YTD)?

As of the latest data, Bridgebio Pharma (BBIO) has a year-to-date price change of -44.28%. Over the past month, the stock has experienced a price change of -13.37%. Over the last three months, the change has been -10.45%. Over the past six months, the figure is -23.64%. Looking at a longer horizon, the five-year price change stands at -22.46%.

help

Is Bridgebio Pharma (BBIO) a profitable company?

Bridgebio Pharma (BBIO) has a net income of -$653.25M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 73.71% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -6.85K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $9.3M, although specific revenue growth data is currently not available. The gross profit is $6.86M. Operating income is noted at -$607.37M. Furthermore, the EBITDA is -$509.9M.

help

What is the market capitalization of Bridgebio Pharma (BBIO)?

Bridgebio Pharma (BBIO) has a market capitalization of $4.23B. The average daily trading volume is 22.42, indicating the stock's liquidity and investor engagement.

News

BRIDGEBIO PHARMA

GENE THERAPY

CONGENITAL ADRENAL HYPERPLASIA

CAH

Sep 11, 2024

BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

BRIDGEBIO PHARMA

EQUITY GRANTS

RESTRICTED STOCK UNITS

NEW EMPLOYEES

Jul 5, 2024

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

HEALTH

CLINICAL STUDY

Jun 18, 2024

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

MAJOR SHAREHOLDER ANNOUNCEMENTS

Jun 10, 2024

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CALENDAR OF EVENTS

Jun 6, 2024

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference